£150,000 Synthetic-Data Sandbox
Proposed 10–14-week programme to examine the reference implementation with synthetic data only.
Decision gate: Reproducible tests, technical assessment, portability and deployment findings.
NashMarkAI Investment · Sovereign Infrastructure
Fund Validation. Establish Delivery. Scale Internationally.
A staged capital and validation pathway for sovereign infrastructure across sectors and jurisdictions, beginning with a proposed £150,000 independent synthetic-data programme.
Staged programme
Five investment and deployment stages
Investment is structured around evidence-based decision gates. The NHS implementation is a published technical reference; the opportunity extends to multiple institutional sectors and international markets.
Institutional Pilot Readiness
Sector-specific integration, delivery partners, procurement and assurance planning, initially through a UK deployment pathway.
Decision gate: Defined sponsor, controls, acceptance criteria and approvals before any live use.
Institutional Delivery
Controlled deployments combining customer-controlled infrastructure, engineering, hardware, integration and support contracts.
Decision gate: Validated customer demand, operating model and economics.
International Market Rollout
Locally operated deployments through regional partners, with infrastructure and governance adapted to national requirements.
Decision gate: Jurisdiction-specific legal, security and operational validation.
Cross-Sector Replication
Adapt the underlying platform pattern to further regulated institutional uses across government, utilities, industry and finance.
Decision gate: Separate sector-specific technical, commercial and safety assessment.
Validation basis
Current evidence and limitations
Executable Reference Software
NashMarkAI publishes an executable v0.1.0 reference implementation using synthetic data.
12/12 Tests · 100/100 Hashes
An independent reconstruction assessment reports that 12/12 repository tests were reproduced and 100/100 embedded file hashes matched.
Not Production Approval
These findings concern the evaluated reference material, not production clinical safety, customer adoption or sector-specific approval.
Investment discussion
Funding & Partnership Enquiries
The initial £150,000 programme is one funding stage, not the capital required for the complete international rollout. Later stages require their own investment decisions and evidence.